Shandong University, or SDU – under the direct jurisdiction of the Ministry of Education – is a key comprehensive university with a long and honorable history, a broad variety of disciplines, strong academic strength and distinctive characteristics, which has had a great influence both at home and abroad. In 2017, the SDU was chosen as one of the first group of China's high-level universities to be listed in the double first-class university program released by the central government of China.

Shandong University has developed by leaps and bounds in recent years. At present, 18 subjects have been listed in the top one percent of subjects in the Essential Science Indicators (ESI), an index showing the competitiveness of a subject published by the Institute for Scientific Information. In addition, five of the university’s subjects – chemistry, engineering, material sciences, clinical medicine, pharmacology and toxicology – were listed in the top 1‰ in the ESI rankings. SDU has also established cooperation with nearly 200 universities in more than 30 countries or regions.

Shandong University is a comprehensive university in China with full-fledged academic disciplines. There are at present 12 general disciplines for undergraduates and postgraduates: philosophy, economics, law, education, literature, history, science, engineering, agriculture, medicine, management and the fine arts. There are 44 first-level doctorate programs, 51 first-level master's degree programs, 95 programs for undergraduates and 42 post-doctorate research programs – forming a complete system for the cultivation of first-class talent. With professional research advantages and excellent human resource, SDU publishes scientific journals in different subjects regularly, including chemistry, physics, materials science, biology, clinical medicine, energy, civil engineering, control science, mathematics, computer, etc., promoting discipline exchange and enhancing international influence.

Shandong Qidu Pharmaceutical Co., Ltd., founded in 1976 and formed the Qidu Pharmaceutical Group in 2013. Qidu Pharma is a comprehensive and research-based drug production enterprise which produces IV solutions, oral preparations, APIs and so on.The company has got more than 170 manufacturing approval numbers. Qidu Pharma is committed to the research of IV solutions and pharmacy intravenous admixture technology. The company has a professional sales team and a technical support department and it can provide intravenous drugs combination schemes and pharmacy intravenous admixture technology supports in the whole variety for all kinds of medical institutions. 

The company operates a national enterprise technology center and a postdoctoral research workstation. It has established several innovation platforms, including the Peking University Health Science Center-Qidu Pharmaceutical Innovative Formulations Joint Lab, the Shandong University-Qidu Drug R&D Center, the Shandong Key Laboratory of Lead Compound Druggability Optimization and Evaluation, and the Shandong Engineering Research Center for Novel Oral Dosage Forms. Focusing on its ten therapeutic areas, the company has significantly increased R&D investment, obtaining 220 drug production approvals, with 28 products (42 specifications) passing or being deemed equivalent in consistency evaluations. It holds 257 authorized patents and currently has 131 products under development.

In the coming period, Qidu Pharma will continue to enhance its high-level independent innovation capabilities, steadfastly implement an international development strategy, and strive to become a leading, globally recognized technology-driven health industry group, making greater contributions to China’s healthcare sector and global human health.